Moreover, we further identified that regorafenib, a multi-kinase inhibitor that has been approved for chemo-refractory metastatic CRC patients23, modulates PTP1B/PITX-1/p120RasGAP signaling in CRC. This evidence concerns the gene RASA1 and colorectal carcinoma.